（於中華人民共和國註冊成立的股份有限公司） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Jiangxi Rimag Group Co., Ltd. 江西一脈陽光集團股份有限公司 （股份代號：2522） 自願公告 完成首批數據交易 茲提述江西一脈陽光集團股份有限公司（「本公司」）日期為2025年4月2日的公告 （「該公告」），內容有關本公司首批在上海數據交易所上架的CT胸部病變標注數據 （「數據集」）。除另有說明外，本公告所用詞彙與該公告所界定者具有相同涵義。 董事會欣然宣佈，於2025年8月25日，數據集正式通過北京國際大數據交易所 （「北數所」）合規審核並成功上架（上架產品號：PD2025082117370118）。本公司 的附屬公司北京一脈信息作為數據提供方，與一家從事數據技術及應用的公司 （「數據使用方」）及北京國際大數據交易所有限責任公司訂立了數據交易三方合作 合同（「數據交易三方合作合同」），並於2025年9月1日本集團根據數據交易三方 ...

Group 1 - The Chinese AI healthcare sector is experiencing a "dual wave of policy and technology" this summer, with the State Council's recent release of the "Opinions on Deepening the Implementation of 'Artificial Intelligence +'" which elevates AI in healthcare to a national strategic level [1] - The goal set by the Opinions is to achieve an AI-assisted diagnosis coverage rate of over 70% in grassroots medical institutions by 2027, marking a significant step towards the large-scale and standardized application of AI technology in healthcare [1] Group 2 - Under the influence of favorable policies, industry technology breakthroughs are reaching critical milestones, exemplified by the announcement from Yilai Sunshine (02522), which plans to launch the world's first AI-assisted diagnostic product for chest CT scans based on a medical imaging foundation model by October 2025 [2] - This product signifies a transition from the "single disease small model" era to a "foundation large model-driven" 2.0 era in medical imaging AI, filling a gap in the global market [2] - Yilai Sunshine's strong network of imaging centers, high-quality data accumulation, and robust AI R&D capabilities position it as a leader in the industry, creating significant barriers to entry for competitors [2] Group 3 - Yilai Sunshine's strategy includes deep collaborations with partners like Huawei and iFlytek in various areas such as grassroots healthcare and AI diagnostics, promoting the industrialization of medical AI [3] - The establishment of regional shared imaging centers and specialized medical alliances aims to replicate the diagnostic capabilities of top-tier hospitals in rural areas, contributing to the equitable distribution of medical resources [3] - The company is evolving from a traditional imaging service provider to an AI healthcare platform with capabilities across data, algorithms, and application scenarios, enhancing its competitive edge in AI development [3] Group 4 - From an investment perspective, Yilai Sunshine's first-mover advantage is rapidly converting into commercial value, with expectations of AI products being included in the medical insurance payment system, opening up market opportunities across B-end (medical institutions), G-end (government public health projects), and C-end (health management) [4] - The company is positioned at a critical intersection of "technological breakthroughs, policy support, and market expansion," with the anticipated launch of AI products in October 2025 likely to lead to significant growth in both performance and valuation [4]

Core Viewpoint - The company, Yipai Yangguang (02522), has announced a share placement to raise approximately HKD 562 million, with a focus on expanding its capabilities in data and artificial intelligence within the medical imaging sector [1] Group 1: Share Placement Details - Yipai Yangguang plans to place 35 million shares at a discount of about 12.53%, aiming to raise net proceeds of approximately HKD 562 million [1] - Approximately 40% of the net proceeds will be allocated to the development of data and AI capabilities, specifically in medical imaging data mining, annotation, and cleaning [1] - About 30% of the net proceeds will be used for expanding the company's medical imaging center business through self-investment or acquisitions, targeting both domestic and overseas markets, including Hong Kong and Singapore [1] Group 2: Financial Performance - For the six months ending June 30, 2025, the company reported revenue of RMB 467 million, a year-on-year increase of 12.89% [1] - Gross profit was reported at RMB 137 million, with a significant increase in net profit attributable to shareholders of RMB 16.44 million, reflecting a year-on-year growth of 328.65% [1] - The company anticipates that its newly established imaging center projects will gradually commence operations in the second half of 2025, coinciding with the expected recovery of national medical equipment update demands by the end of 2024 [1]

Core Viewpoint - The company reported a significant increase in mid-term performance for the six months ending June 30, 2025, with revenue reaching 467 million RMB, a year-on-year increase of 12.89% [1] Financial Performance - Revenue for the reporting period was 467 million RMB, with a gross profit of 137 million RMB [1] - Shareholder profit attributable to the company was 16.44 million RMB, reflecting a substantial year-on-year increase of 328.65% [1] - Basic earnings per share were reported at 0.046 RMB [1] Business Strategy and Market Position - The increase in revenue was primarily driven by a rise in customer numbers, despite macroeconomic slowdowns and adjustments in the reform process [1] - The company maintained stable revenue growth in its core imaging center services, even amidst industry cyclical adjustments [1] - The company is actively adjusting its business pace and expanding its medical imaging center network through investments, mergers, and the incubation of industrial funds [1] Future Outlook - New imaging center projects are expected to gradually commence operations in the second half of 2025 [1] - The ongoing release of national medical infrastructure policies is anticipated to boost business revenue significantly, with a recovery in demand for medical equipment expected by the end of 2024 [1] - The company is developing more flexible and diverse products, which have led to a notable increase in customer numbers, injecting new vitality into revenue growth [1]

Core Viewpoint - The global medical imaging sector is undergoing a collective revaluation, driven by the acceleration of AI transforming from a technological concept into commercial value and clinical efficiency [1][5]. Group 1: Company Performance - HeartFlow's stock surged to a high of $33.24, a 74.9% increase from its IPO price of $19, achieving a market capitalization of $2.698 billion [1]. - RadNet's stock reached a historical high of $68.41, with a total market value of $5.26 billion [1]. - RadNet is the largest independent imaging center operator in the U.S., with over 380 centers and projected revenue of $1.83 billion in 2024, alongside a net profit of $38.84 million [2]. Group 2: AI Integration and Business Model - RadNet's growth is attributed to AI commercialization and acquisitions, while HeartFlow showcases AI's disruptive potential in specialized imaging [2]. - One Medical Sunshine (一脉阳光) differentiates itself through a "traditional service sharing model + AI data ecosystem," indicating a unique development path [2]. - One Medical Sunshine operates 106 imaging centers across 16 provinces, with an annual scanning volume exceeding 10 million [3]. Group 3: Financial Projections - One Medical Sunshine expects revenue of 450-480 million yuan for the first half of 2025, representing a year-on-year growth of 8.8%-16% [2]. - The company anticipates a net profit of 14.5-16.5 million yuan, a significant increase of 1350%-1550% year-on-year [2]. Group 4: Market Potential and Valuation - The U.S. third-party imaging penetration rate is 40-50%, with a growth rate of less than 5%, while China's penetration is only about 1%, with a projected market size of 18.6 billion yuan by 2030 and a compound annual growth rate of 30.7% [5]. - One Medical Sunshine's market capitalization of 6.3 billion HKD is significantly undervalued compared to its business scale and market potential, with a price-to-book ratio of 4.045, lower than the industry average [4]. - The company is positioned to benefit from the explosive growth potential in the Chinese market, with a unique combination of profitability and scarce licenses in the third-party imaging sector [5].

Core Viewpoint - The Shanghai government has introduced measures to enhance corporate investment in fundamental research, aiming to strengthen the role of enterprises in technological innovation and improve original innovation capabilities in key and future industries [1] Group 1: Policy Measures - The "Explorer Program" is a detailed policy under the measures to solidify effective policies and expand the scale of cooperating enterprises [1] - The measures include both "giving fish" and "teaching to fish" policies to encourage corporate investment in fundamental research [2] - Financial incentives are provided for companies based on their annual investment in fundamental research, with subsidies ranging from 200 million to 1 billion yuan [2] Group 2: Corporate Participation - As of now, 22 enterprises have joined the "Explorer Program," including state-owned, private, and foreign companies [3] - The program encourages collaboration between enterprises and research institutions to address scientific problems behind technological challenges [3] - Companies like United Imaging Healthcare have successfully launched clinical trials for innovative technologies supported by the program [3] Group 3: Collaborative Innovation - The measures promote deep integration of industry and academia through collaborative innovation centers, enhancing project-based cooperation [4] - United Imaging Healthcare has established partnerships with Shanghai Jiao Tong University and Ruijin Hospital to advance research in medical imaging technology [5] Group 4: Philanthropic Initiatives - The measures support the establishment of public welfare funds by enterprises to promote fundamental research, with matching support from the government [5] - Titan Technology has set up a non-public fundraising foundation to support original research projects in materials science and chemistry [6] - A new public welfare fund initiated by 16 state-owned enterprises aims to support fundamental research, marking a significant step in corporate involvement in scientific exploration [6]

Group 1 - The core viewpoint of the article is the strategic partnership between GaoShang Health Group and United Imaging Group aimed at enhancing patient quality of life through advanced medical imaging and AI technology [1][3]. - The collaboration will focus on building a digital twin service platform for imaging, emphasizing the development of AI diagnostic products in areas such as oncology and cardiovascular diseases [5]. - GaoShang Health Group has previously integrated high-end medical equipment from United Imaging, enhancing patient medical experiences [3]. Group 2 - The partnership will establish a collaborative platform for industry-academia-research cooperation, initiating multi-center research projects and developing a talent pipeline in imaging diagnostics [5]. - In 2024, United Imaging plans to enter the consumer market, leveraging its expertise in blood glucose management to create a diabetes health management center in collaboration with GaoShang Health [5]. - The strategic cooperation is positioned as a significant step towards the intelligent upgrade of medical imaging services in China, aiming to improve the diagnosis of major diseases [5].

Group 1 - The training session for medical imaging physicians was held at Peking University Health Science Center Zibo Hospital, emphasizing the importance of medical imaging technology in precision medicine [1][3] - Liu Luming, Vice President of the Shandong Provincial Association of Social Medical Institutions, highlighted the need for continuous skill improvement among participants to contribute to the high-quality development of social medical services [1][3] - The training featured expert reports on advancements in pancreatic imaging and integrated MRI solutions for ischemic stroke, showcasing the latest knowledge and practical skills in the field [3] Group 2 - The training program aims to regularly conduct tiered training to enhance diagnostic service capabilities in social medical institutions, with a focus on standardizing diagnosis and cultivating talent [3] - The initiative is part of a broader effort to promote high-quality imaging technology in grassroots healthcare, contributing to the construction of a healthier Shandong province [3]

Core Points - The 8th China International Import Expo will be held from November 5 to 10, 2025, at the National Exhibition and Convention Center in Shanghai [1] Group 1: Exhibition Details - The technology and equipment exhibition area will feature over 80 Fortune 500 companies and industry leaders, including ten major industrial electrical companies, five top elevator companies, and four major water treatment companies [1] - The medical exhibition area will showcase ten Fortune 500 pharmaceutical companies, three leading medical imaging companies, and three top radiation therapy equipment companies, highlighting innovations in drug and medical device development, biomedicine technology, and cross-border digital diagnosis and treatment [1] - The automotive exhibition area has been upgraded to include automotive and smart mobility, displaying global vehicles, auto parts, aftermarket services, multi-modal transportation, and low-altitude economy innovations with a focus on intelligence, safety, and sustainability [1] Group 2: Innovation and Projects - The innovation incubation area will reach a new scale, gathering over 500 cutting-edge global innovation projects, covering four major tracks: digital economy, green low-carbon, life sciences, and manufacturing technology [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Jiangxi Rimag Group Co., Ltd. 江西一脈陽光集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2522） 自願公告 收購眾雅診斷股權 本公告由江西一脈陽光集團股份有限公司（「本公司」，連同其附屬公司統稱為「本 集團」）董事（「董事」）會（「董事會」）自願作出，以通知本公司股東（「股東」）及本 公司的潛在投資者有關本集團的最新業務發展。 董事會欣然宣佈，於2025年6月9日（交易時段後），本公司擁有55.0%權益的附屬 公司湖南一脈陽光醫學影像診斷中心有限公司（「湖南一脈」）（作為買方）、長沙市 眾雅健康產業集團有限公司（作為賣方，「賣方」）與長沙眾雅醫學影像診斷有限公 司（「眾雅診斷」）訂立股權轉讓協議（「股權轉讓協議」），據此，湖南一脈將向賣方 收購眾雅診斷的100.0%股權（「收購事項」），總代價為人民幣29,500,000元。 於本公告日期，湖南 ...